UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States

Authors


Corresponding author:
Henry W. Lim, M.D.
Department of Dermatology
Henry Ford Medical Center - New Center One
3031 West Grand Blvd, Suite 800
Detroit, MI 48202
USA
Tel: +1 313 916 4060
Fax: +1 313 916 1477
e-mail: hlim1@hfhs.org

Abstract

Background: The efficacy and safety of UVA1 (340–400 nm) phototherapy were established by studies from European countries.

Purpose: Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States.

Methods: A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed.

Results: Two-third of the patients showed a fair to good response (26–100% improvement) and one-third of the patients showed a poor response (0–25% improvement). Diseases with a moderate to good response (51–100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I–III responded better that those with a darker skin type.

Conclusion: UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.

Ancillary